Infliximab pharmacokinetics in inflammatory bowel disease patients

Therapeutic Drug Monitoring

Volumn 30, Issue 4, 2008, Pages 523-529

  Ternant, David ^a,b,c   Aubourg, Alexandre ^a,b,d   Magdelaine Beuzelin, Charlotte ^a,b,e   Degenne, Danielle ^a,b,e   Watier, Hervé ^a,b,e   Picon, Laurence ^d   Paintaud, Gilles ^a,b,c,f  

^a UNIVERSITÉ DE TOURS   (France)

^b CNRS   (France)

^c Departments of Pharmacology Toxicology   (France)

^d Departments of Gastroenterology   (France)

^e Departments of Immunology   (France)

^f CHU BRETONNEAU   (France)

Author keywords

Inflammatory bowel diseases; Infliximab; Monoclonal antibodies; Pharmacokinetics; Therapeutic drug monitoring

Indexed keywords

ADALIMUMAB; DRUG ANTIBODY; INFLIXIMAB; ANTIINFLAMMATORY AGENT; MONOCLONAL ANTIBODY;

AGE; ANTIBODY DETECTION; ARTICLE; BODY WEIGHT; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; COMPARTMENT MODEL; CONTINUOUS INFUSION; CONTROLLED STUDY; CROHN DISEASE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MONITORING; DRUG SUBSTITUTION; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MALE; MULTIPLE CYCLE TREATMENT; POPULATION RESEARCH; PRIORITY JOURNAL; SEX DIFFERENCE; ULCERATIVE COLITIS; ADULT; ALGORITHM; ENTERITIS; HALF LIFE TIME; METABOLISM; MIDDLE AGED; POPULATION; STATISTICAL ANALYSIS; STATISTICAL MODEL;

ADULT; ALGORITHMS; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; DATA INTERPRETATION, STATISTICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HALF-LIFE; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED; MODELS, STATISTICAL; POPULATION; YOUNG ADULT;

EID: 58149132609     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e318180e300     Document Type: Article

References (25)

1. Klotz U, Teml A, Schwab M. Clinical pharmacokinetics and use of infliximab. Clin Pharmacokinet. 2007;46:645-660.
2. Ternant D, Paintaud G. Pharmacokinetics and concentration-effect relationships of therapeutic monoclonal antibodies and fusion proteins. Expert Opin Biol Ther. 2005;5(Suppl 1):S37-47.
3. Bendtzen K, Geborek P, Svenson M, et al. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab. Arthritis Rheum. 2006;54:3782-3789.
4. St Clair EW, Wagner CL, Fasanmade AA, et al. The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2002;46:1451-1459.
5. Wolbink GJ, Voskuyl AE, Lems WF, et al. Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis. Ann Rheum Dis. 2005;64:704-707.
6. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med. 2003; 348:601-608.
7. Maser EA, Villela R, Silverberg MS, et al. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol. 2006;4:1248-1254.
8. de Vries MK,Wolbink GJ, Stapel SO, et al. Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation. Ann Rheum Dis. 2007;66:1252-1254.
9. Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, doubleblind trial. Lancet. 2005;366:1367-1374.
10. de Vries MK, Wolbink GJ, Stapel SO, et al. Inefficacy of infliximab in ankylosing spondylitis is correlated with antibody formation. Ann Rheum Dis. 2007;66:133-134.
11. Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 1998;41:1552-1563.
12. Cornillie F, Shealy D, D'Haens G, et al. Infliximab induces potent antiinflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn's disease. Aliment Pharmacol Ther. 2001;15:463-473.
13. Ternant D, Mulleman D, Degenne D, et al. An enzyme-linked immunosorbent assay for therapeutic drug monitoring of infliximab. Ther Drug Monit. 2006;28:169-174.
14. Katz JA, Antoni C, Keenan GF, et al. Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritis. Am J Gastroenterol. 2004;99:2385-2392.
15. Iacona I, Lazzarino M, Avanzini MA, et al. Rituximab (IDEC-C2B8): validation of a sensitive enzyme-linked immunoassay applied to a clinical pharmacokinetic study. Ther Drug Monit. 2000;22:295-301.
16. Ng CM, Bruno R, Combs D, et al. Population pharmacokinetics of rituximab (anti-CD20 monoclonal antibody) in rheumatoid arthritis patients during a phase II clinical trial. J Clin Pharmacol. 2005;45: 792-801.
17. Kloft C, Graefe EU, Tanswell P, et al. Population pharmacokinetics of sibrotuzumab, a novel therapeutic monoclonal antibody, in cancer patients. Invest New Drugs. 2004;22:39-52.
18. Zhou H, Jang H, Fleischmann RM, et al. Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis. J Clin Pharmacol. 2007;47: 383-396.
19. Berinstein NL, Grillo-Lopez AJ, White CA, et al. Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol. 1998;9:995-1001.
20. Wiseman GA, Kornmehl E, Leigh B, et al. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials. J Nucl Med. 2003;44:465-474.
21. Morell A, Terry WD, Waldmann TA. Metabolic properties of IgG subclasses in man. J Clin Invest. 1970;49:673-680.
22. Candon S, Mosca A, Ruemmele F, et al. Clinical and biological consequences of immunization to infliximab in pediatric Crohn's disease. Clin Immunol. 2006;118:11-19.
23. Bartelds GM, Wijbrandts CA, Nurmohamed MT, et al. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis. 2007;66:921-926.
24. Furuya Y, Ozeki T, Takayanagi R, et al. Theory based analysis of antiinflammatory effect of infliximab on Crohn's disease. Drug Metab Pharmacokinet. 2007;22:20-25.
25. EMEA. Scientific discussion for Remicade. 2005. EMEA/H/C/240/II/61. Available at: http://www.emea.europa.eu/humandocs/PDFs/EPAR/Remicade/ EMEA-H-240-II-61-AR.pdf Accessed October 2007.